文献速递头颈外科

pT1-2N0M0头颈部腺样囊性癌的辅助放疗

Adjuvant Radiotherapy in pT1-2N0M0 Head and Neck Adenoid Cystic Carcinoma.
PubMed 文献 · Laryngoscope · 2025-03-27

基于2006至2018年美国国家癌症数据库回顾性分析738例pT1-2N0M0头颈部腺样囊性癌患者,其中379例(51.4%)接受辅助放疗。接受辅助放疗者5年总生存率为94%对86%、10年总生存率为85%对73%,均高于未接受辅助放疗者(p<0.001)。多因素分析显示辅助放疗与更高的总生存率相关(aHR 0.30,95%CI 0.13-0.69,p=0.005),作者认为低分期淋巴结阴性患者应接受辅助放疗以优化长期生存。

要点

  • 738例pT1-2N0M0头颈部腺样囊性癌中379例(51.4%)接受了辅助放疗。
  • 辅助放疗者5年总生存率94%对86%、10年总生存率85%对73%,均高于未放疗者(p<0.001)。
  • 多因素分析中辅助放疗与更高总生存率相关(aHR 0.30,95%CI 0.13-0.69,p=0.005)。

核心结论

  • 约半数pT1-2N0M0头颈部腺样囊性癌患者未接受辅助放疗,作者认为这可能偏离循证推荐并提示多学科诊疗质量改进机会。
  • 辅助放疗与更高的5年和10年总生存率相关,作者认为低分期淋巴结阴性头颈部腺样囊性癌患者应接受辅助放疗以优化长期生存。

研究设计与样本

  • 回顾性分析2006至2018年美国国家癌症数据库(National Cancer Database)中pT1-2N0M0头颈部腺样囊性癌患者,共738例符合纳入标准。
  • 采用多因素二元逻辑回归和Cox回归模型进行分析。

主要发现

  • 738例中379例(51.4%)接受了辅助放疗。
  • 口腔原发部位与接受辅助放疗的较低几率相关(aOR 0.64,95%CI 0.43-0.96,p<0.05)。
  • 颈部淋巴结清扫与接受辅助放疗的较高几率相关(aOR 1.58,95%CI 1.09-2.28,p<0.025)。
  • PSM与接受辅助放疗的较高几率相关(aOR 1.84,95%CI 1.30-2.60,p<0.025)。
  • 接受辅助放疗者5年总生存率为94%对86%、10年总生存率为85%对73%,均高于未接受辅助放疗者(p<0.001)。

临床怎么用

  • 作者认为,低分期淋巴结阴性头颈部腺样囊性癌患者应接受辅助放疗以优化长期生存。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence regarding the indications and survival benefit of adjuvant radiotherapy (aRT) in pT1-2N0M0 head and neck adenoid cystic carcinoma (HNAdCC) is inconclusive. Lower-staged, node-negative HNAdCC therefore represents a rare, moderate-risk disease category with high variation in adjuvant management depending on patient and physician preferences. Our study investigates the impact of aRT on overall survival (OS) in this rare, moderate-risk disease category. METHODS: The 2006 to 2018 National Cancer Database was retrospectively reviewed for patients with pT1-2N0M0 HNAdCC. Multivariable binary logistic and Cox regression models were implemented. RESULTS: Of 738 patients satisfying inclusion criteria, 379 (51.4%) underwent aRT. Oral cavity primary site (aOR 0.64, 95% CI 0.43-0.96) was associated with lower odds of undergoing aRT (p < 0.05); neck dissection (aOR 1.58, 95% CI 1.09-2.28) and PSM (aOR 1.84, 95% CI 1.30-2.60) were associated with higher odds of undergoing aRT (p < 0.025). Patients undergoing aRT had higher 5-year (94% vs. 86%) and 10-year OS (85% vs. 73%) than those not undergoing aRT (p < 0.001). Adjusting for patient demographics, pathologic features, and treatment, age at diagnosis (aHR 1.05, 95% CI 1.02-1.08, p < 0.001) was associated with worse OS; aRT (aHR 0.30, 95% CI 0.13-0.69, p = 0.005) was associated with higher OS. CONCLUSION: Approximately half of patients with pT1-2N0M0 HNAdCC did not undergo aRT, highlighting a possible deviation from evidence-based recommendations and an opportunity for quality improvement in the multidisciplinary care of patients. aRT was associated with higher 5-year and 10-year OS, suggesting that patients with lower-staged, node-negative HNAdCC should be offered aRT to optimize long-term survival.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Kaki PC, Patel AM, Haleem A, et al. Adjuvant Radiotherapy in pT1-2N0M0 Head and Neck Adenoid Cystic Carcinoma. Laryngoscope. 2025. PMID: 40145621. doi:10.1002/lary.32156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。